Miracor secures FDA breakthrough status for its heart attack device

Red blood cells
The device’s balloon intermittently blocks blood from flowing out through the coronary sinus veins, redirecting and pushing circulation to the oxygen-deprived areas of the heart muscle. (Wikimedia Commons)

Belgian devicemaker Miracor Medical received a breakthrough designation from the FDA for its treatment designed to limit the damage of a heart attack. 

Miracor’s PiCSO Impulse System is delivered to the heart’s coronary vessels through a minimally invasive procedure in patients experiencing an ST-elevated myocardial infarction, also known as a STEMI. 

The device’s balloon intermittently blocks blood from flowing out through the coronary sinus veins, redirecting and pushing circulation to the oxygen-deprived areas of the heart muscle. In addition, the rhythmic increases in pressure help wash out potentially damaging agents released by heart cells during an infarction, according to the company. 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The PiCSO system’s unique mechanism of action aims to reduce infarct size, which is associated with heart failure hospitalizations and mortality in the months following a heart attack. 

RELATED: Miracor raises $30M to close in on heart attack device nod

Last month (PDF), Miracor began a randomized study in Western Europe comparing the PiCSO therapy to conventional percutaneous coronary interventions in anterior STEMI patients, with the first patient being treated in the U.K. The study aims to enroll 144 patients, measuring cardiac function after six months and following participants for at least three years.  

In 2018, the company raised $30 million in a series D venture capital round, with the goal of funding a large U.S. trial, as well as moving the company’s operations from Austria to Belgium. Investors included SFPI, SRIW and Meusinvest, as well as a grant from the Wallonia regional government. 

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.